What readers are saying

Timmerman sets the standard for excellence in biotech journalism.

Thong Le, CEO, Accelerator

There are a lot of writers commenting on the biopharmaceutical industry. Only a few really matter. Luke has proven himself to be one of them.

Richard Pops, Chairman and CEO, Alkermes

Luke has the rare ability to ask just the right questions to get underneath the standard “company line” and provide real insight.

Harlan Robins, associate member, Fred Hutchinson Cancer Research Center, founder, Adaptive Biotechnologies

Timmerman is always ahead of the game.

Robert T. Nelsen, managing director, ARCH Venture Partners

Biotech social media is easy to obtain, but is a firehose of data, information, and speculation. The savvy professional needs less noise and more actionable signal. Luke Timmerman finds and writes about that signal.

Atul Butte, director, Institute for Computational Health Sciences, UCSF

Luke’s ability to blend the implications of science with the exigencies of business creates an idiosyncratic and insightful read.

Vicki Sato, professor of management practice, Harvard Business School

Luke Timmerman knows the deep secret of biotech: success requires technology plus people.

Joshua Boger, founder, Vertex Pharmaceuticals

With job interviews a few months away, and my graduate school career winding down, I needed a crash course in the biopharma and healthcare industries. Timmerman Report came to the rescue! Luke’s condensed, opinionated and informed posts about the depth and breadth of the industries allowed me to become quickly conversant and stay updated about this rapidly changing space. I got the job I wanted!

Anasuya Mandal, Doctoral Candidate, Department of Chemical Engineering at MIT

Timmerman Report has been fantastic for our students and postdocs here at MIT’s Koch Institute, based on overwhelmingly positive feedback. As many of our trainees move on to diverse positions within the biotech ecosystem, TR provides them with invaluable working knowledge, insight, and language beyond academia.

Anne Deconinck, Executive Director, Koch Institute for Integrative Cancer Research at MIT

Luke speaks science, speaks medicine and speaks business. Oh, and he writes really well, too. Subscribing to TR is like having another analyst on the team.

David Sable, Special Situations Life Sciences Fund

TR is essential reading at EcoR1 Capital. Luke’s thoughts and insights not only report on the biotech sector but help shape it.

Oleg Nodelman, Founder, Managing Director, EcoR1 Capital

I enjoy the sharp writing and no-bullshit tone in Timmerman Report. This is journalism worth paying for.

Kevin Judice, CEO, DiCE Molecules